The Effect of Atorvastatin on Cerebral Edema,Neurological Function,and IL-33 Levels in Patients with Hypertensive Intracerebral Hemorrhage

Miao Ye; Sui Xin; Sun Weiming

Abstract：Objective To investigate the effect of atorvastatin on interleukin-33(IL-33)levels in patients with hypertensive in-tracerebral hemorrhage(HCH).Methods 80 patients with HCH were randomly divided into a control group and an observation group.The control group was given routine treatment,while the observation group was given oral atorvastatin on the basis of routine treatment.At the end of treatment,the total effective rate,absolute and relative volume of cerebral edema,national institutes of health stroke scale(NIHSS),glasgow coma index(GCS)score neuron specific enolase(NSE),central nervous system specific pro-tein(S100β),interleukin-33(IL-33),interleukin-1β(IL-1β),tumor necrosis factor-α(TNF-α),and C-reactive protein(CRP)levels were compared between the two groups.Results After treatment,the total effective rate of the observation group was 95%higher than that of the control group by 78%(x2 =5.168,P<0.05).Before treatment,the absolute and relative volumes of brain edema in the two groups before treatment were similar,and there was no statistical difference between the two groups(t-value= 0.181,0.797,P>0.05);after treatment,the absolute andrelative volumes of brainedema inbothgroups were lower thanthose be-fore treatment(t=15.323,15.034,24.425,13.038,P<0.05)and the absolute and relative volumes of brain edema in the obser-vation group were lower than those in the control group(t=3.171,13.265,P<0.05).There was no statistically significant differ-ence in NIHSS and GCS scores between the two groups before treatment(t=0.778,0.967,P>0.05);after treatment,the NIHSS scores of the two groups were lower than that before treatment,while the GCS scores were higher than that before treatment(t = 27.370,23.857,7.101,4.443,P<0.05);after treatment,the NIHSS score of the observation group was lower than that of the control group,while the GCS score was higher than that of the control group(t=7.247,2.713,P<0.05).There were no significant differences in NSE and S100β levels between the two groups before treatment(t=0.425,0.349,P>0.05);the levels of NSE and S100β in two groups after treatment were lower than before treatment(t=6.065,4.436,20.109,7.030,P<0.05);after treat-ment,the levels of NSE and S100β in observation group were lower than those in control group(t=2.278,12.818,P<0.05).There were no significant differences in IL-33,IL-1β,TNF-α and CRP levels between the two groups before treatment(t=0.043,1.265,0.708,0.157,P>0.05);the levels of IL-33,IL-1β,TNF-α and CRP in two groups after treatment were lower than those before treatment(t=5.120,2.119,11.610,4.207,8.378,3.604,7.552,5.420,P<0.05);after treatment,the lev-els of IL-33,IL-1β,TNF-α and CRP in observation group were lower than those in control group(t=3.703,3.336,2.389,5.087,P<0.05).There was no statistically significant difference in the incidence of adverse reactions between the two groups(x2= 0.312,P>0.05).Conclusion Atorvastatin had a significant therapeutic effect on HCH patients,significantly promoting the absorp-tion of brain edema,slowing down neurological deficits,alleviating consciousness disorders,and reducing NSE and S100 β inflamma-tory factor levels increase IL-33 levels.